Christopher J. Morl
Nessuna posizione attualmente
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Steven Hoerter | M | 53 | 6 anni | |
| Matthew Sherman | M | 68 | 5 anni | |
| Jeff Held | M | 55 | 6 anni | |
| Daniel Martin | M | 49 | 6 anni | |
| Sally Jackson | F | - | 23 anni | |
| Rodrigo Ruiz Soto | M | - | 7 anni | |
| Timothy Woodthorpe | M | - | 24 anni | |
| Graham Rivers | M | - | 26 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Ron Squarer | M | 57 | 5 anni | |
| Susan Kelley | M | 69 | 5 anni | |
| Ian Maurice Gray Prosser | M | 81 | 9 anni | |
| Jean-Pierre Garnier | M | 75 | 8 anni | |
| Murray Stewart | M | 63 | 17 anni | |
| Julian Heslop | M | 70 | 13 anni | |
| Peter Traber | M | 69 | 3 anni | |
| John David Coombe | M | 79 | 5 anni | |
| Franklin Friedman | M | 66 | 5 anni | |
| Edward Benz | M | 78 | 5 anni | |
| Liam Ratcliffe | M | 60 | 2 anni | |
| Michael Ross | M | 75 | 4 anni | |
| Robert J. DiVasto | M | 68 | 2 anni | |
| Denis Brodsky | M | 53 | 5 anni | |
| Thierry Loriot | M | - | - | |
| Steven Gelone | M | 56 | 2 anni | |
| Lawson Macartney | M | 66 | 12 anni | |
| David Wheadon | M | 66 | 5 anni | |
| Robin M. Young | M | 57 | 7 anni | |
| Sjoerd Wadman | M | - | 12 anni | |
| Michael Owen | M | 73 | 9 anni | |
| Roger Connor | M | - | 24 anni | |
| Scott Fields | M | 69 | 5 anni | |
| Marie Paule Richard | M | 72 | 1 anni | |
| David Rodman | M | 69 |
miRagen Therapeutics, Inc. /Old/
 miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | - |
| John Lepore | M | - | 15 anni | |
| Stephen Ruddy | M | 60 | - | |
| Julie VanOrsdel Daves | F | - |
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | 2 anni |
| Clare Khan | M | 72 | 11 anni | |
| Melissa Beelen | F | - | 12 anni | |
| David Rowe | M | 57 | 20 anni | |
| Edgar Cale | M | 60 | 21 anni | |
| Jon Ellis | M | 57 | 21 anni | |
| Daniel G. Marquess | M | 55 | 4 anni | |
| Aimee L. Jackson | M | - |
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | - |
| Steve Damment | M | - | 17 anni | |
| Oliver Rosen | M | 59 | 4 anni | |
| Vivid Sehgal | M | 56 | 6 anni | |
| Brian Blakey | M | 61 | 6 anni | |
| Dean Hakanson | M | 72 | 7 anni | |
| Caroline Chevalier | F | - | 3 anni | |
| Anthony S. Murabito | M | - | 19 anni | |
| Edward Littler | M | - | - | |
| Arthur Levin | M | 70 |
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | 2 anni |
| Eddie J. Gray | M | 64 | 12 anni | |
| Christopher Chipman | M | 50 | 2 anni | |
| George Poste | M | 79 | 7 anni | |
| Ronaldo Hermann Schmitz | M | 85 | 9 anni | |
| Michael D. Rogers | M | 68 | 6 anni | |
| Eric Carter | M | 72 | - | |
| Peter Goodfellow | M | 72 | 8 anni | |
| J. Michael Hamilton | M | 75 | 5 anni | |
| Ursula B. Bartels | F | 66 | 11 anni | |
| Martin Rosenberg | M | 78 | 5 anni | |
| James R. Beery | M | 83 | 1 anni | |
| Robert Ruffolo | M | 74 | 16 anni | |
| Tim Tyson | M | 71 | 6 anni | |
| John Apeler Keller | M | 60 | - | |
| Dean Mitchell | M | 68 | 15 anni | |
| Roger L. Hawley | M | 71 | 14 anni | |
| Joseph Schachle | M | 59 | 3 anni | |
| Tamar Howson | F | 75 | 9 anni | |
| Lucy Shapiro | M | 83 | 5 anni | |
| Franco di Muzio | M | - | 8 anni | |
| Rupert Bondy | M | 62 | - | |
| Robert G. Pietrusko | M | 76 | 1 anni | |
| Luc Mainville | M | 60 |
Alethia Biotherapeutics, Inc.
 Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | 3 anni |
| Margaret Dalesandro | M | 77 | 2 anni | |
| Douglas B. Snyder | M | 60 | 6 anni | |
| Peter Strong | M | - | 3 anni | |
| David Lawrence | M | 61 | 13 anni | |
| Ford Calhoun | M | - | - | |
| Ian Gilham | M | 64 | - | |
| Adrian Rawcliffe | M | 52 | 17 anni | |
| Lisa Porter | M | 60 | 5 anni | |
| Michael V. Milburn | M | - | 10 anni | |
| Elaine Jones | M | 69 | - | |
| Gary Patou | M | 65 | 5 anni | |
| Argeris Karabelas | M | 71 | 6 anni | |
| Paul Magrez | M | - | 4 anni | |
| Wissam Al-Adani | M | 50 | 6 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Regno Unito | 70 | 78.65% |
| Stati Uniti | 18 | 20.22% |
| Canada | 1 | 1.12% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Christopher J. Morl
- Contatti personali
